EGFR and non-small cell lung carcinoma: In patients with EGFR-mutant NSCLC, osimertinib is now integrated across the disease continuum - as adjuvant therapy after complete resection, neoadjuvant therapy prior to surgery, and consolidative therapy following definitive chemoradiotherapy for unresectable locally advanced disease.